You just read:

Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

News provided by

Novo Nordisk

Jun 20, 2017, 18:57 ET